This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly Update: News, Analysis and Insider Insights Delivered Straight To Your Inbox

Quanticate lauds benefits of its cloud trial data management platform

Share this article

Quanticate says its new cloud-based data verification platform cuts trial costs and accelerates timelines.

The CRO launched the Remote Source Data Verification (RSDV) platform last week, explaining it allows the verification of multiple clinical research sites’ source data to be completed remotely by a specialist team at a centralized location.

It said it “built the platform to help clinical trial sponsors reduce Clinical Research Associate (CRA) travel costs and time, negate the challenges associated with movement restriction, increase data integrity and accelerate the detection of site issues, thus improving quality.”

The service also includes access to a team with experience in the global conduct of clinical trials and extensive therapeutic, GCP and regulatory knowledge according to Quanticate.

CEO David Underwood cited the disruption caused by coronavirus as the target market for the technology.

“Throughout the COVID-19 pandemic, there have been significant challenges for clinical trial sponsors and sites alike resulting in renewed emphasis on creating remote approaches to improve efficiencies and adapt to travel restrictions.

“Our new Remote Source Data Verification (RSDV) platform will help to ensure that our customers operate more efficiently and safely while delivering clinical trial data with high integrity.”

Quanticate spoke about the platform during a discussion focused on decentralized trials earlier this year, citing effective data management, analysis and security as the foundation for any such study.

Decentralized studies have grown in popularity over the past year – for obvious reasons. According to a recent survey 44% of pharma and CRO sector professionals asked said they had adopted remote patient monitoring or plan to do so in the next year.

In addition, a majority – 65% – of survey respondents who said they are using RPM cited concerns related to the coronavirus pandemic as their primary driver for using the technology.

Image: iStock/LeoWolfert

Share this article

Sign up for Clinical Insider email updates